Navigation Links
First in Nation: notMYkid Educational Center Is Now a Reality Thanks to a Partnership Between Chrysler, Barrett-Jackson and notMYkid
Date:1/12/2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2009)... to avoid oysters harvested from San Antonio Bay ... U.S. Food and Drug Administration is advising consumers to ... on or after Nov. 16 due to reports of ... harvested from this area, which is located on the ... ) ,, The FDA, along with the Centers ...
(Date:12/6/2009)... growth factor, researchers say , , SUNDAY, Dec. 6 ... from the main tumor to other parts of the ... TGFb, which may prove a promising target for new ... , Previous studies have shown that TGFb (transforming growth ... this new study, a team from Cancer Research UK ...
(Date:12/6/2009)... -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) ... Phase 2b 003-A1 study, known as the 003 ... pre-treated relapsed and refractory multiple myeloma patients. These ... Symposium at the 51st annual meeting of the ... Enrollment in this trial is complete (n=269), and ...
(Date:12/6/2009)... A new study provides welcome news for patients with ... , The condition is estimated to impact 62,000 ... an abnormal clot forms in a vein and restricts ... some cases, the clot may detach from its point ... lungs, causing a potentially fatal condition known as a ...
(Date:12/6/2009)... Attorney Joseph W. Belluck of Belluck & Fox, LLP says dangerous ... holiday seasons. , ... New York, NY (PRWEB) December ... holiday season, they should be alert to reports of recalls due ... injury lawyer., , ,“Close to 230,000 children visit hospital emergency rooms ...
Breaking Medicine News(10 mins):Health News:FDA, CDC, and States Investigating Norovirus Illnesses Linked to Oysters 2Health News:Breast Cancer's Spread Now Better Understood 2Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 2Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 3Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 4Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 5Health News:New drug shows promise for those with clotting disorders: McMaster researcher 2Health News:Belluck & Fox Law Firm Urges Caution When Buying Toys This Holiday Season 2Health News:Belluck & Fox Law Firm Urges Caution When Buying Toys This Holiday Season 3
... the United States receive fewer vascular surgeries than the ... according to new research, which also finds that Hispanics ... Reasons for the disparities are not fully understood, but ... variations. , Published in the November Journal of Vascular ...
... of preventing deaths and severe complications arising from chickenpox ... research published ahead of print in Archives of Disease ... others likely to be at risk of contracting or ... UK. But vaccination programmes for children have been introduced ...
... with a new partner while overseas, finds research published ... , And they are apparently opting for British or ... the chances of HIV infection, but seemingly unawares of ... The findings are based on interviews with a random ...
... and Technologies of Senegal is hosting the third annual ... a 10-year effort to boost the ability of African ... The conference, which runs from Nov. 12-15, will focus ... about how to improve access to usable water. ...
... SHENZHEN, China and NEW YORK, Nov. 9 ... directly operated stores,China Nepstar Chain Drugstore Ltd (NYSE: ... today on the New York Stock Exchange. ... its,initial public offering at US$16.20 each. Gross proceeds ...
... Nov. 9 Cash Technologies, Inc.,(Amex: ... subsidiary, Claim-Remedi,Services, Inc. has entered into a ... Inc. ("HPS") to market Claim-Remedi,s healthcare,revenue cycle ... the first,healthcare receivables financing program in the ...
Other Medicine News:Health News:New study questions disparities in vascular surgery among Hispanics 2Health News:Chicken pox vaccination should be introduced for children in the UK 2Health News:1 in 5 young Britons has sex with someone new while abroad 2Health News:Safe water is theme of African science academies conference in Senegal 2Health News:China Nepstar Chain Drugstore (NPD) Begins Trading on NYSE 2Health News:Cash Technologies Subsidiary Signs Services and Licensing Agreement With Health Payment Systems 2Health News:Cash Technologies Subsidiary Signs Services and Licensing Agreement With Health Payment Systems 3
(Date:12/4/2009)... WASHINGTON, Dec. 4 Chemistry World recently highlighted ... Research and Manufacturers of America ( PhRMA ) that ... and related conditions. ,, The report found that ... antivirals. These drugs are either in human clinical trials or ...
(Date:12/4/2009)... (NYSE Amex: PIP ), a biodefense company ... announced today that the Company is presenting results ... in an inhalation anthrax model in the New ... being presented during an oral session at the ...
(Date:12/4/2009)... OrthoAccel Technologies, Inc., developers of the AcceleDent ... enhance orthodontics, announced the availability of a new ... , a leader in professional education for many ... focuses on patient views about orthodontic treatment, a ...
Breaking Medicine Technology:U.S. Pharmaceutical Companies Developing 97 New Drugs and Vaccines to Fight HIV/AIDS 2PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 2PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 3PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 4PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 5PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 6AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 2AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 3AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 4GenVec Announces Third Quarter 2009 Results Conference Call 14630 1GenVec Announces Third Quarter 2009 Results Conference Call 14630 2Osteotechs MagniFuse 28TM 29 Technology Used in First U S Surgery 5781 1Osteotechs MagniFuse 28TM 29 Technology Used in First U S Surgery 5781 2Osteotechs MagniFuse 28TM 29 Technology Used in First U S Surgery 5781 3Osteotechs MagniFuse 28TM 29 Technology Used in First U S Surgery 5781 4Santaris Pharma A S Expands Executive Team Appoints Chief Medical Officer and Chief Business Officer to Advance Proprietary RNA targeted Drug Develop 5776 1Santaris Pharma A S Expands Executive Team Appoints Chief Medical Officer and Chief Business Officer to Advance Proprietary RNA targeted Drug Develop 5776 2Santaris Pharma A S Expands Executive Team Appoints Chief Medical Officer and Chief Business Officer to Advance Proprietary RNA targeted Drug Develop 5776 3Santaris Pharma A S Expands Executive Team Appoints Chief Medical Officer and Chief Business Officer to Advance Proprietary RNA targeted Drug Develop 5776 4
Used for complex diagnostic and interventional procedures....
... St. Jude Medical offers a ... for use with percutaneous catheter ... of intravascular catheters. Our diagnostic ... lengths and incorporate a proprietary ...
... VISION Coronary Stent System is Guidant's first ... stents. Cobalt chromium is stronger and more ... chromium stent can have similar strength and ... with struts that are only .0032" thick. ...
... The CYPHER Sirolimus-eluting Coronary ... antiproliferative drug, called "sirolimus", a ... stent delivery platform. Upon placement, ... wall and impedes the process ...
Medicine Products: